Yorktown Management & Research Co Inc Decreases Stock Holdings in Insmed, Inc. (NASDAQ:INSM)

Yorktown Management & Research Co Inc lowered its holdings in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 46.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,850 shares of the biopharmaceutical company's stock after selling 5,120 shares during the period. Yorktown Management & Research Co Inc's holdings in Insmed were worth $446,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Elequin Capital LP purchased a new position in shares of Insmed in the 4th quarter valued at about $28,000. Steward Partners Investment Advisory LLC increased its holdings in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares in the last quarter. NBC Securities Inc. purchased a new position in shares of Insmed in the 1st quarter valued at about $49,000. Versant Capital Management Inc increased its holdings in Insmed by 546.3% during the 1st quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock valued at $53,000 after acquiring an additional 590 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 411 shares in the last quarter.

Insmed Trading Down 2.2%

Shares of INSM traded down $2.25 during mid-day trading on Friday, hitting $99.49. The company had a trading volume of 34,467,302 shares, compared to its average volume of 2,309,118. The business's 50-day simple moving average is $78.01 and its 200-day simple moving average is $75.54. The company has a quick ratio of 5.44, a current ratio of 5.86 and a debt-to-equity ratio of 11.38. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $106.83. The stock has a market cap of $18.87 billion, a PE ratio of -16.72 and a beta of 0.80.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The company had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. During the same period in the prior year, the business posted ($1.06) earnings per share. Insmed's revenue was up 22.9% on a year-over-year basis. Sell-side analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Buying and Selling

In other Insmed news, Director Clarissa Desjardins acquired 1,895 shares of the firm's stock in a transaction on Tuesday, May 20th. The stock was bought at an average cost of $66.87 per share, for a total transaction of $126,718.65. Following the completion of the purchase, the director now directly owns 1,895 shares in the company, valued at $126,718.65. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Sara Bonstein sold 57,765 shares of the business's stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $101.78, for a total transaction of $5,879,321.70. Following the sale, the chief financial officer now owns 93,536 shares of the company's stock, valued at approximately $9,520,094.08. This represents a 38.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 488,752 shares of company stock valued at $43,199,826. Insiders own 3.00% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Jefferies Financial Group restated a "buy" rating on shares of Insmed in a report on Tuesday, June 10th. Leerink Partners raised their target price on shares of Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a report on Tuesday, June 10th. Wells Fargo & Company raised their target price on shares of Insmed from $107.00 to $119.00 and gave the company an "overweight" rating in a report on Wednesday, June 11th. The Goldman Sachs Group raised their target price on shares of Insmed from $100.00 to $112.00 and gave the company a "buy" rating in a report on Wednesday, June 11th. Finally, Mizuho raised their target price on shares of Insmed from $96.00 to $110.00 and gave the company an "outperform" rating in a report on Wednesday, June 11th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $106.80.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.